All In Biotech

Drug Trial Radar · NCT06544473

Determining Dose Equivalence Between Oral and Transdermal Estrogen Treatment in Women With Turner Syndrome

Determining Dose Equivalence Between Oral and Transdermal Estrogen Treatment in Women With Turner Syndrome - A Randomized Study

Last checked: Nov 20, 2026Latest source record: Aug 23, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

50

Planned (sponsor's estimate)

Start

Nov 29, 2021

Primary completion

Dec 31, 2026

Study completion Dec 31, 2026

Sponsor

Lead sponsor
Aarhus University HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
University of Aarhus
First posted
Aug 9, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This 5-week, phase IV randomized crossover trial aims to compare the effects of oral versus transdermal estrogen replacement therapy (ERT) in women with Turner syndrome (TS). The objective is to establish the equipotency between the two estradiol regimens by evaluating various estradiol-dependent surrogate markers. The study involves 50 women with TS, aged 18-50 years, who are randomized to receive either oral or transdermal ERT for 14 days, followed by a crossover to the alternate treatment for another 14 days, with a one-week washout period in between. Blood tests are conducted at baseline, after the first 14 days of treatment, after the washout period, and after the final 14 days of treatment. The investigators anticipate that this study will provide clinicians with a better understanding of ERT in treating women with TS.

Conditions

  • Turner Syndrome
  • Hypogonadism; Ovarian
  • Hormone Replacement Therapy
  • Estrogen Replacement Therapy
  • Estrogen Deficiency

Interventions

  • 17-beta estradiolDrug

    Treatment with orally administered estrogen for 14 days

  • 17-beta estradiolDrug

    Treatment with transdermally administered estrogen for 14 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. EquipotencyTime frame: After 14 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Department of Endocrinology and Internal Medicine, Aarhus University Hospital

    Aarhus, Aarhus N, Denmark · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.